STOCK TITAN
  1. Home
  2. News
  3. VRPX

Virpax Pharmaceuticals Inc - VRPX STOCK NEWS

Welcome to our dedicated news page for Virpax Pharmaceuticals (Ticker: VRPX), a resource for investors and traders seeking the latest updates and insights on Virpax Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Virpax Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Virpax Pharmaceuticals's position in the market.

News
Virpax Pharmaceuticals Reports 2023 Year-End Results
Rhea-AI Summary
Virpax Pharmaceuticals, Inc. announced its financial results for the twelve months ended December 31, 2023, highlighting regained compliance with Nasdaq, settlement agreements, and progress in developing non-addictive pain management products. The company reported positive initial results from a pilot study of Probudur™ by the U.S. Army Institute of Surgical Research, with plans for further studies. Virpax also emphasized its focus on non-addictive product candidates, government grants, and partnerships to advance pain assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
none
-
News
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price
Rhea-AI Summary
Virpax Pharmaceuticals, Inc. announced a 1-for-10 reverse stock split of its common stock, aiming to regain Nasdaq compliance and attract more investors. The split will reduce outstanding shares from 11.7 million to 1.2 million, with no change in ownership percentage. The company's CEO expressed optimism about future prospects despite challenges in the capital markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.71%
Tags
stock split
-
News
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Rhea-AI Summary
Virpax Pharmaceuticals, Inc. has entered into a term sheet to settle litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc. The settlement includes cash payments totaling $6 million and royalties on net sales of certain products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.71%
Tags
none
News
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
Rhea-AI Summary
Virpax Pharmaceuticals, Inc. announced positive initial results from a pilot study for Probudur, a product designed to reduce or eliminate the need for opioids after surgery or trauma. The study, performed by the U.S. Army Institute of Surgical Research, showed that both doses of Probudur reduced incision-induced pain behaviors in a rat model. Virpax has also highlighted its success in securing government grants to fund clinical trials for its products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.97%
Tags
none
-
News
Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting
Rhea-AI Summary
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) announced the approval of a reverse stock split to maintain compliance with Nasdaq's minimum bid price requirement. The reverse split ratio will be between 1-to-2 to 1-to-20, with the effective date to be announced later if the minimum bid price requirement is not met by April 8, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
-
News
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
Rhea-AI Summary
Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) received a notice from Nasdaq stating non-compliance with filing its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023. The company filed a Notification of Late Filing on Form 12b-25 and continues to evaluate a litigation decision. Virpax is working diligently to finalize and file the Quarterly Report.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
none
News
Virpax Pharmaceuticals Announces Leadership Transition
Rhea-AI Summary
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) announced the resignation of CEO and Chairman Anthony P. Mack due to ongoing litigation. The Board appointed Gerald Bruce as CEO and Dr. Eric Floyd as Chairman. Mr. Bruce has extensive experience in commercial operations and pharmaceutical sales, while Dr. Floyd brings over 25 years of experience in regulatory affairs and quality assurance. The company aims to begin first-in-human trials under the new leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
management
-
News
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments
Rhea-AI Summary
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) announced financial results for Q3 2023 and recent developments. The company shared positive preclinical study results for Probudur, its lead product candidate for post-operative pain, and plans to file an IND for Envelta, a non-addictive pain product candidate, in mid-2024. Virpax also extended its CRADA with the USAISR and appointed a new President and CEO for Novvae Pharmaceuticals. The company's Q3 2023 financial results showed a decrease in general and administrative expenses and research and development expenses compared to the same period in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.18%
Tags
earnings
-
News
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review
Rhea-AI Summary
Virpax Pharmaceuticals expects to submit an Investigational New Drug Application (IND) for Envelta in mid-2024, allowing clinical trials to begin. Envelta is a non-addictive pain product candidate for acute and chronic pain. It utilizes a novel intranasal drug delivery system called Molecular Envelope Technology (MET) to bypass the blood-brain barrier. Preclinical studies in rats and dogs have shown positive efficacy with minimal adverse effects. Virpax plans to advance Envelta through preclinical development and conduct first-in-human trials in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
none
News
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research
Rhea-AI Summary
Virpax Pharmaceuticals extends CRADA with U.S. Army Institute of Surgical Research for Probudur
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
none
Stock VRPX logo
Virpax Pharmaceuticals Inc

Nasdaq:VRPX

VRPX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

VRPX Stock Data

4.16M
1.14M
25.72%
3.26%
2.55%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Berwyn

About VRPX

virpax pharmaceuticals specializes in developing new drug delivery systems across various indications to increase compliance and maximize the ability to achieve full therapeutic efficacy. we develop branded pharmaceutical products for pain management by using cutting-edge technology to enhance patients'​ quality of life, all while creating value for our investors and partners. we are focused on becoming a global leader in non-opioid pain management by developing and delivering innovative pharmaceutical products to our customers. virpax is committed to collaborating with its network of u.s. and global partners to advance the development of proprietary drug platforms that will produce the next generation of branded pharmaceutical products.